Dr. Anang Shelat is an expert in chemical informatics and assay development, with an expanding portfolio of innovative and collaborative research efforts. His scientific journey began at Harvard, continued at UCSF, and ultimately led to postdoc fellowship and faculty appointment at St. Jude. Dr. Shelat and his team developed invaluable analytical tools for drug screening that have helped shape preclinical therapeutic development, and clinical efforts, across the hematological, brain, and solid tumor landscape.
The Shelat lab is focused on identifying and exploiting weaknesses in multiple types of cancers and tumors. They are particularly interested in targeting the DNA damage response in pediatric cancers. Their lab uses chemical biology and machine learning to understand how we can identify and target these weaknesses. Finding these vulnerabilities will ultimately lead to guide therapies with existing drugs or lead to new drug targets.